FATE Live signals | Maximize Profits with Getagraph.com

BUY 103152 min ago

@ $6.43

Issued: 14 Feb 2024 @ 15:38

Return: -39.81%

Previous signal: Feb 14 - 13:20

Previous signal: Sell

Return: -1.30 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide...

Stats
Today's Volume	3.57M
Average Volume	2.76M
Market Cap	440.47M
EPS	$0 ( 2024-02-26 )
Next earnings date	( $-0.480 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.36
ATR14	$0.0120 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Redmile Group, Llc	Buy	3 636 364	Pre-Funded Warrants to Purchase Common Stock
2024-03-04	Dulac Edward J Iii	Sell	2 447	Common Stock
2024-02-01	Wolchko J Scott	Buy	500 000	Stock Option (Right to Buy)
2024-02-01	Tahl Cindy	Buy	425 000	Stock Option (Right to Buy)
2024-02-01	Dulac Edward J Iii	Buy	425 000	Stock Option (Right to Buy)

INSIDER POWER
40.57
Last 99 transactions
Buy: 17 254 718 \| Sell: 8 388 589

Volume Correlation

Long: -0.46 (neutral)

Short: -0.97 (very strong negative)

Signal:(37.837) Neutral

Fate Therapeutics Inc Correlation

10 Most Positive Correlations
STRC	0.974
ONCS	0.971
WISA	0.97
TTCF	0.969
IMRX	0.968
LUMO	0.964
GROM	0.961
VIRX	0.957
IMCC	0.956
MEDS	0.956

10 Most Negative Correlations
NWFL	-0.96
IBEX	-0.95
MNKD	-0.947
PWOD	-0.942
LRFC	-0.935
HZNP	-0.934
XOMAO	-0.931
PDD	-0.931
IMMR	-0.93
ISIG	-0.93

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fate Therapeutics Inc Correlation - Currency/Commodity

-0.16
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.35
( neutral )

Fate Therapeutics Inc Financials

Annual	2023
Revenue:	$63.53M
Gross Profit:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2023
Revenue:	$63.53M
Gross Profit:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2022
Revenue:	$96.30M
Gross Profit:	$82.54M (85.71 %)
EPS:	$-2.63

FY	2021
Revenue:	$55.85M
Gross Profit:	$55.85M (100.00 %)
EPS:	$-2.24

Financial Reports:

No articles found.

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Realtime updates for Fate Therapeutics Inc [FATE]

Upcoming Earnings Alert